Series details
Sub-series Health Technology Assessment (HTA)
Series:
ISSN:
No ISSN
|
Available item(s) in this sub-series (135)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Statins for the primary prevention of cardiovascular events / Audrey Cordon / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)
Statins for the primary prevention of cardiovascular events [printed text] / Audrey Cordon, Author ; Christophe de Meester , Author ; Sophie Gerkens , Author ; Dominique Roberfroid , Author ; Chris De Laet , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2019 . - 219 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 306C) .
ISSN : D/2019/10.273/07 : € 0,00
Languages : English (eng)
Descriptors: Classification
WG 120 Cardiovascular diseases (General or not elsewhere classified)
Indexation
2018-01 ; Cardiovascular diseases ; Costs and Cost Analysis ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Primary Prevention ; R306Contents note: TABLE OF FIGURES 6 -- TABLE OF TABLES 8 -- LIST OF ABBREVIATIONS 12 -- SCIENTIFIC REPORT 16 -- 1 BACKGROUND 16 -- 2 OBJECTIVES 18 -- 3 HISTORICAL AND CURRENT STATIN USE IN BELGIUM 18 -- 3.1 INTRODUCTION 18 -- 3.2 METHODS 19 -- 3.2.1 Global data 19 -- 3.2.2 Individual data 19 -- 3.3 STATINS AVAILABLE ON THE BELGIAN MARKET 21 -- 3.3.1 Statins 21 -- 3.3.2 Combination products containing a statin 23 -- 3.4 REIMBURSEMENT RULES FOR STATINS 24 -- 3.4.1 Basic rules 24 -- 3.4.2 Indications and indicators 24 -- 3.5 NUMBER OF STATIN USERS (GLOBAL DATA) 25 -- 3.6 VOLUMES OF PRESCRIBED STATINS (GLOBAL DATA) 26 -- 3.6.1 Statins 26 -- 3.6.2 Combination products containing a statin 27 -- 3.6.3 All products containing a statin 27 -- 3.7 COST OF STATINS (GLOBAL DATA) 28 -- 3.7.1 Total cost 28 -- 3.7.2 Reimbursements 28 -- 3.7.3 Patient contribution 29 -- 3.8 SUMMARY OF THE GLOBAL DATA 30 -- 3.9 STATIN USERS (INDIVIDUAL DATA) 30 -- 3.9.1 Users and New users 30 -- 3.9.2 Characteristics of users and new users of the last years of registration 2014-2015 32 -- 3.10 PRIMARY VS. SECONDARY PREVENTION (INDIVIDUAL DATA) 36 -- 3.11 ADHERENCE (INDIVIDUAL DATA) 38 -- 3.11.1 Regular and occasional users 38 -- 3.11.2 Factors associated with poor adherence 41 -- 3.11.3 Adherence in primary prevention 44 -- 3.11.4 Probability of stopping a statin for a period longer than 365 days in new users for primary prevention 45 -- 3.11.5 Risk score assessment in regular versus occasional new users 47 -- 3.12 EXPENSES (INDIVIDUAL DATA) 48 -- 3.12.1 Brand drug or generic 48 -- 3.12.2 Evolution of mean expenditures per DDD over time 48 -- 3.13 SUMMARY OF THE INDIVIDUAL DATA 50 -- 4 CLINICAL EFFECTIVENESS AND HARMS 51 -- 4.1 INTRODUCTION 51 -- 4.2 METHODS 51 -- 4.3 RESULTS FROM THE SEARCH STRATEGY 52 -- 4.4 CHARACTERISTICS AND QUALITY APPRAISAL OF THE SELECTED SYSTEMATIC REVIEW. 52 -- 4.5 EVIDENCE ON EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION 53 -- 4.5.1 Preliminary remarks 53 -- 4.5.2 Baseline risk for CVD in the included patients and follow-up time 54 -- 4.5.3 Overall results 54 -- 4.5.4 Sensitivity analyses 55 -- 4.5.5 All-cause mortality 56 -- 4.5.6 Cardiovascular mortality 56 -- 4.5.7 Fatal and non-fatal myocardial infarction 56 -- 4.5.8 Fatal and non-fatal stroke 57 -- 4.5.9 Revascularization 57 -- 4.5.10 Composite cardiovascular outcome 57 -- 4.6 EVIDENCE ON HARMS FROM RCT’S AND OBSERVATIONAL RESEARCH 57 -- 4.6.1 Evidence on harms from RCTs in the selected systematic review on primary prevention 57 -- 4.6.2 Evidence on harms from the previous KCE report 58 -- 4.6.3 Recent reviews on harms associated with statin use 59 -- 4.7 CONCLUSIONS 62 -- 4.7.1 Conclusions on effectiveness 62 -- 4.7.2 Conclusions on harms 63 -- 5 COST-EFFECTIVENESS 63 -- 5.1 INTRODUCTION 63 -- 5.2 METHODS 63 -- 5.2.1 Search strategy 63 -- 5.2.2 Selection criteria 64 -- 5.3 RESULTS OF THE ECONOMIC SEARCH STRATEGY 65 -- 5.3.1 Results of the search strategy of reviews 65 -- 5.3.2 Results of the search strategy of primary studies 65 -- 5.4 OVERVIEW OF REVIEWS OF ECONOMIC EVALUATIONS 65 -- 5.4.1 Description of the selected reviews 65 -- 5.4.2 Main results of the studies selected in these reviews of economic evaluations 66 -- 5.4.3 Main results of the models developed in these reviews of economic evaluations 68 -- 5.4.4 Recommendations from these reviews of economic evaluations 69 -- 5.4.5 Summary of results 71 -- 5.5 OVERVIEW OF SELECTED PRIMARY STUDIES 71 -- 5.5.1 Comparison of various CVD risk and age thresholds 71 -- 5.5.2 Patient with diabetes or chronic kidney disease 80 -- 5.5.3 ‘Polypills’ compared to plain statins, antihypertensive guidelines and current practice 86 -- 5.5.4 Summary of results 90 -- 5.6 CONCLUSIONS FOR THE COST-EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS 92 -- 6 SUMMARY AND DISCUSSION 92 -- 6.1 SCOPE OF THIS HEALTH TECHNOLOGY ASSESSMENT 92 -- 6.2 HISTORICAL AND CURRENT USE OF STATINS IN BELGIUM 93 -- 6.2.1 History of the marketing of statins in Belgium 93 -- 6.2.2 Global statin use in Belgium 93 -- 6.2.3 Individual statin use in Belgium 94 -- 6.3 RISK ASSESSMENT 95 -- 6.4 EFFICACY AND HARMS OF STATIN USE IN PRIMARY PREVENTION 97 -- 6.4.1 Efficacy 97 -- 6.4.2 Harms 98 -- 6.5 COST-EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION 98 -- 6.6 APPLICABILITY OF THE FINDINGS TO BELGIUM 100 -- 6.7 WHO SHOULD RECEIVE STATIN-BASED PRIMARY PREVENTION? 100 -- 6.8 LIMITATIONS OF THE CURRENT EVIDENCE 101 -- 6.9 OVERALL CONCLUSION 101 -- APPENDICES 102 -- APPENDIX 1. HISTORICAL AND CURRENT USE OF STATINS IN BELGIUM 102 -- APPENDIX 1.1. SUBGROUPS ANALYSES FOR USERS AND NEW USERS 102 -- APPENDIX 1.2. ADHERENCE 122 -- APPENDIX 1.3. CURRENT PRICES OF STATINS IN BELGIUM 124 -- APPENDIX 2. CLINICAL BENEFITS AND HARMS 126 -- APPENDIX 2.1. SEARCH STRATEGIES FOR SYSTEMATIC REVIEWS AND RCTS 126 -- APPENDIX 2.2. SEARCH STRATEGY FOR RCTS IN MEDLINE 137 -- APPENDIX 2.3. SELECTION OF STUDIES FROM SEARCH STRATEGY 139 -- APPENDIX 2.4. INCLUSION AND EXCLUSION CRITERIA 140 -- APPENDIX 2.5. QUALITY APPRAISAL 141 -- APPENDIX 2.6. CHARACTERISTICS OF INCLUDED RCTS 146 -- APPENDIX 2.7. META-ANALYSES 152 -- APPENDIX 3. COST-EFFECTIVENESS 154 -- APPENDIX 3.1. SEARCH STRATEGIES OF REVIEWS OF ECONOMIC EVALUATIONS 154 -- APPENDIX 3.2. SEARCH STRATEGIES OF PRIMARY ECONOMIC EVALUATION 163 -- APPENDIX 3.3. SELECTION PROCESS OF ECONOMIC EVALUATIONS 178 -- APPENDIX 3.4. RESULTS FROM REVIEWS OF ECONOMIC EVALUATIONS 181 -- APPENDIX 3.5. RESULTS FROM SELECTED PRIMARY STUDIES 194 -- APPENDIX 3.6. ANNUAL COST IN BELGIUM (2018) 206 -- REFERENCES 209 Link for e-copy: http://doi.org/10.57598/R306C Format of e-copy: PDF (4,3 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4501 Steunharten bij de behandeling van terminaal hartfalen / Mattias Neyt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
Steunharten bij de behandeling van terminaal hartfalen : Synthese [printed text] / Mattias Neyt , Author ; Roos Leroy , Author ; Carl Devos , Author ; Hans Van Brabandt , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2016 . - 12 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 264As) .
ISSN : D/2016/10.273/26 : € 0,00
Studie 2015-07
Languages : Dutch (nla)
Descriptors: Indexation
2015-07 ; Cost-Benefit Analysis ; Heart Failure ; Heart-Assist Devices ; R264 ; Technology Assessment, Biomedical
Classification
WG 169.5 Artificial heart. Heart-lung machineAbstract: Naar schatting krijgen jaarlijks meer dan 10 000 Belgen te horen dat ze aan hartfalen lijden. Een beperkt aantal onder hen met terminaal hartfalen komt in aanmerking voor harttransplantatie, maar door een gebrek aan donorharten zijn de wachtlijsten lang. In afwachting kan een steunhart dat de hartfunctie overneemt, worden ingeplant. Het RIZIV betaalt er jaarlijks 50 van terug. Het Federaal Kenniscentrum voor de Gezondheidzorg (KCE) ging na of het kosten-effectief is om ook patiënten die niet meteen in aanmerking komen voor een transplantatie, ermee te behandelen.
Vanuit medisch standpunt hebben steunharten een reële meerwaarde want zij verbeteren zowel de overleving als de levenskwaliteit. Maar hun meerkost in vergelijking met de klassieke behandeling ligt erg hoog. Vanuit gezondheids-economisch standpunt zijn er daarom geen argumenten voor een uitbreiding van de terugbetaling van steunharten.Contents note: VOORWOORD 1 -- SYNTHESE 2 -- 1. STEUNHARTEN VOOR DE AANPAK VAN HARTFALEN 3 -- 1.1. WAT IS HARTFALEN? 3 -- 1.2. WAT IS DE OORZAAK VAN HARTFALEN? 3 -- 1.3. HOE VAAK KOMT HARTFALEN VOOR, EN BIJ WIE? 3 -- 1.4. HOE WORDT HARTFALEN BEHANDELD? 3 -- 1.5. HARTTRANSPLANTATIE: HOGERE OVERLEVING EN LEVENSKWALITEIT, MAAR TE WEINIG DONORHARTEN 3 -- 1.6. DE LVAD OF HET STEUNHART: EEN MECHANISCH ALTERNATIEF 4 -- 1.7. HET GEBRUIK VAN STEUNHARTEN: VOOR WELKE PATIËNTEN? 5 -- 1.8. STEEDS TOENEMENDE VRAAG IN BELGIË 6 -- 1.9. METHODE 7 2. DE KLINISCHE WERKZAAMHEID VAN STEUNHARTEN 8 -- 2.1. VERLENGING VAN DE LEVENSDUUR EN VERBETERING VAN DE LEVENSKWALITEIT. 8 -- 2.2. COMPLICATIES: VOORAL RISICO OP BLOEDINGEN 9 -- 3. DE KOSTPRIJS VAN STEUNHARTEN TEGENOVER DE KLASSIEKE BEHANDELING 9 -- 4. KOSTEN-EFFECTIVITEIT BIJ GEBRUIK ALS DESTINATION THERAPY EN BRIDGE TO CANDIDACY 10 -- 4.1. STEUNHARTEN ALS DESTINATION THERAPY (DT): €82 000 PER GEWONNEN KWALITEITSVOL LEVENSJAAR 10 -- 5. DISCUSSIE 12 -- AANBEVELINGEN 13 Link for e-copy: http://doi.org/10.57598/R264AS Format of e-copy: PDF (530 Kb)) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3831 The Implantable Cardioverter Defibrillator: a Health Technology Assessment / Hans Van Brabandt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)
The Implantable Cardioverter Defibrillator: a Health Technology Assessment [printed text] / Hans Van Brabandt , Author ; Mattias Neyt , Author ; Nancy Thiry ; Robert van den Oever ; Patrick Galloo ; Johan Vanoverloop ; Laurence Kohn ; Mark Leys ; Antonine Wyffels ; Dirk Ramaekers . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2007 . - x, 243 p : ill. ; 30 cm.. - (KCE Reports. Health Technology Assessment (HTA); 58C) .
ISSN : D/2007/10.273/23 : 0 €
Etude nr 2006-07
Languages : English (eng)
Descriptors: Classification
WG 330 Disorders of the heart beat
Indexation
2006-07 ; Defibrillators, Implantable ; R58Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1619 Copies(0)
Status No copy The non-invasive prenatal test (NIPT) for trisomy 21 / Frank Hulstaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2014)
The non-invasive prenatal test (NIPT) for trisomy 21 : health economic aspects [printed text] / Frank Hulstaert, Author ; Mattias Neyt , Author ; Wilfried Gyselaers, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2014 . - 106 p. : ill, ; A4. - (KCE Reports. Health Technology Assessment (HTA); 222) .
ISSN : D/2014/10.273/36 : € 0,00
Languages : English (eng)
Descriptors: Indexation
2013-54 ; Diagnostic Techniques, Obstetrical and Gynecological ; Down Syndrome ; Nuchal Translucency Measurement ; Prenatal Diagnosis ; R222Contents note: SCIENTIFIC REPORT 8 -- 1 COST-EFFECTIVENESS OF NIPT 8 -- 1.1 RESEARCH QUESTIONS AND METHODS 8 -- 1.2 PRENATAL SCREENING FOR DOWN SYNDROME 9 -- 1.2.1 Down syndrome 9 -- 1.2.2 Current screening for Down syndrome 10 -- 1.2.3 Invasive tests for T21 diagnosis 11 -- 1.2.4 NIPT 13 -- 1.2.5 Decisions with regard to pregnancy termination after a T21 diagnosis 14 -- 1.3 LITERATURE SEARCH FOR ECONOMIC EVALUATIONS 14 -- 1.3.1 Search strategy 14 -- 1.3.2 Selection criteria 15 -- 1.4 OVERVIEW OF ECONOMIC EVALUATIONS 17 -- 1.4.1 General information 17 -- 1.4.2 Population 18 -- 1.4.3 Intervention and comparator 18 -- 1.4.4 Screening costs (and costs of Down syndrome) 18 -- 1.4.5 Test characteristics 19 -- 1.4.6 Other assumptions 19 -- 1.4.7 Quality of life 20 -- 1.4.8 Results and sensitivity analysis 20 -- 1.4.9 Authors’ conclusions 21 -- 1.5 DISCUSSION 22 -- 2 COST-EFFECTIVENESS OF NIPT: MODELING EXERCISE FOR BELGIUM 30 -- 2.1 METHODS 30 -- 2.1.1 Analytic technique 30 -- 2.1.2 Perspective 30 -- 2.1.3 Population 31 -- 2.1.4 Intervention and comparator 34 -- 2.1.5 Time horizon and discount rate 36 -- 2.1.6 Input variables 36 -- 2.1.7 Uncertainty 45 -- 2.1.8 Model development, calibration and validation 47 -- 2.2 RESULTS 48 -- 2.2.1 Base case analysis 48 -- 2.2.2 Sensitivity analysis 50 -- 3 DISCUSSION 57 -- 3.1 THE SCREENING PROCESS 57 -- 3.2 THE INVASIVE TEST FOR DIAGNOSIS 59 -- 3.3 DECISIONS WITH REGARD TO PREGNANCY TERMINATION 60 -- 3.4 THE DIFFICULT CHOICE OF THE TIME HORIZON 60 -- 3.5 NIPT 61 -- 3.6 NIPT FOR TRIAGE IN AT RISK WOMEN AFTER CURRENT SCREENING 62 -- 3.7 PRIMARY NIPT SCREENING USING CURRENT TESTING UPTAKE 63 -- 3.8 INCREASED NIPT UPTAKE OF 90% 63 -- 3.9 THE PRICE OF NIPT AND THRESHOLD ANALYSIS 64 -- 3.10 COST-CONSEQUENCES ANALYSIS OR (QA)LYS GAINED 65 -- 4 CONCLUSIONS 67 Link for e-copy: http://doi.org/10.57598/R222C Format of e-copy: PDF (1,1 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3379 Copies(0)
Status No copy The non-invasive prenatal test (NIPT) for trisomy 21 / Frank Hulstaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2014)
The non-invasive prenatal test (NIPT) for trisomy 21 : health economic aspects - Synthesis [printed text] / Frank Hulstaert, Author ; Mattias Neyt , Author ; Wilfried Gyselaers, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2014 . - 25 p. : ill, ; A4. - (KCE Reports. Health Technology Assessment (HTA); 222Cs) .
ISSN : D/2014/10.273/35 : € 0,00
Languages : English (eng)
Descriptors: Indexation
2013-54 ; Diagnostic Techniques, Obstetrical and Gynecological ; Down Syndrome ; Nuchal Translucency Measurement ; Prenatal Diagnosis ; R222Contents note: FOREWORD 1 -- SYNTHESIS 2 -- 1. INTRODUCTION 4 -- 1.1. DOWN SYNDROME 4 -- 1.2. NIPT 4 -- 1.3. SCOPE, RESEARCH QUESTIONS AND METHODS 5 -- 2. LITERATURE REVIEW 6 -- 3. CONTEXT-SPECIFIC MODELLING 6 -- 3.1. PREGNANCIES AND CHILDREN BORN WITH DOWN SYNDROME 6 -- 3.2. CURRENT PRENATAL SCREENING 7 -- 3.3. THE INVASIVE DIAGNOSTIC TEST PROCEDURES 11 -- 3.4. DECISIONS WITH REGARD TO PREGNANCY TERMINATION 11 -- 3.5. OUTCOMES AND TIME HORIZON 12 -- 3.6. INPUT VARIABLES FOR THE MODEL 12 -- 4. RESULTS OF THE MODEL 15 -- 4.1. NIPT FOR TRIAGE IN AT RISK WOMEN AFTER CURRENT SCREENING 15 -- 4.1.1. NIPT in 5% screen positives at a 1:300 risk cut-off 15 -- 4.1.2. NIPT in 20% screen positives at a 1:1700 risk cut-off 15 -- 4.2. PRIMARY NIPT SCREENING 15 -- 4.2.1. Primary NIPT screening with current uptake 15 -- 4.2.2. Increased NIPT uptake of 90% 16 -- 5. CONCLUSIONS 18 -- 5.1. STRENGTHS AND LIMITATIONS OF THE STUDY 18 -- 5.2. INFORMED DECISION MAKING 18 -- 5.3. A HIGHER SENSITIVITY 19 -- 5.4. A HIGHER SPECIFICITY 20 -- 5.5. OPTIONS FOR INTRODUCING NIPT 20 -- RECOMMENDATIONS 21 -- REFERENCES 23 Link for e-copy: https://doi.org/10.57598/R222CS Format of e-copy: PDF (560Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3380 Copies(0)
Status No copy The role of biomarkers in ruling out cerebral lesions in mild cranial trauma / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
PermalinkThe role of biomarkers in ruling out cerebral lesions in mild cranial trauma / Lorena San Miguel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
PermalinkThe use of statins in the primary prevention of cardiovascular disease / Christophe de Meester / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)
PermalinkThreshold values for cost-effectiveness in health care / Irina Cleemput ; Mattias Neyt ; Nancy Thiry ; Chris De Laet ; Mark Leys / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
PermalinkTiotropium in the Treatment of Chronic Obstructive Pulmonary Disease Health Technology Assessment / Mattias Neyt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2009)
PermalinkTowards an expansion of the reimbursement conditions for Hepatitis C therapies? / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
PermalinkTranscatheter aortic valve implantation (TAVI) / Mattias Neyt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkTranscatheter Aortic Valve Implantation (TAVI) / Mattias Neyt / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkTrastuzumab in Early Stage Breast Cancer / Huybrechts, Michel / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)
PermalinkUse of pneumococcal vaccines in the elderly / Adriaan Blommaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
Permalink